Related references
Note: Only part of the references are listed.Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
C. D. DiNardo et al.
BLOOD (2020)
Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial
Abhishek Maiti et al.
BLOOD (2020)
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk et al.
CANCER DISCOVERY (2019)
Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
Justin Taylor et al.
GENES CHROMOSOMES & CANCER (2019)
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
Abhishek Maiti et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
Abhishek Maiti et al.
BLOOD (2019)
Targeting transcription factors in cancer - from undruggable to reality
John H. Bushweller
NATURE REVIEWS CANCER (2019)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)
Thorsten Braun et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape
P. Silva et al.
LEUKEMIA (2017)
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience
Rama Nanah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Xiaojia Niu et al.
CLINICAL CANCER RESEARCH (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Combined Targeting of JAK2 with a Type II JAK2 Inhibitor and mTOR with a TOR Kinase Inhibitor Constitutes Synthetic Activity in JAK2-Driven Ph-like Acute Lymphoblastic Leukemia
Ce Shi et al.
BLOOD (2015)
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
Hagop Kantarjian et al.
BLOOD (2010)
Induction therapy for elderly patients with acute myeliod leukemia
Mike G. Martin et al.
BLOOD REVIEWS (2008)
Share Paper
